Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP.

Greco R, Ciceri F, Noviello M, Bondanza A, Vago L, Oliveira G, Peccatori J, Cieri N, Ruggeri A, Koehl U, Fleischhauer K, Rocha V, Dazzi F, van der Werf SM, Eikema DJ, Terwel SR, Kuball J, Toubert A, Chabannon C, Bonini C; EBMT Cellular Therapy and Immunobiology Working Party (CTIWP).

Bone Marrow Transplant. 2018 Apr 17. doi: 10.1038/s41409-018-0167-8. [Epub ahead of print] No abstract available.

PMID:
29666449
2.

Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies.

Chabannon C, Kuball J, Bondanza A, Dazzi F, Pedrazzoli P, Toubert A, Ruggeri A, Fleischhauer K, Bonini C.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaap9630. doi: 10.1126/scitranslmed.aap9630. Review.

PMID:
29643233
3.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
4.

Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib.

van der Wagen L, Te Boome L, Schiffler M, Nijhof I, Schoordijk M, van Dorp S, van Dijk M, Raymakers R, Petersen E, de Witte M, de Jong N, Bellido M, Bär B, Meijer E, Kuball J.

Bone Marrow Transplant. 2018 Mar 16. doi: 10.1038/s41409-018-0158-9. [Epub ahead of print]

PMID:
29549292
5.

Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation.

Litjens NHR, van der Wagen L, Kuball J, Kwekkeboom J.

Front Immunol. 2018 Mar 1;9:389. doi: 10.3389/fimmu.2018.00389. eCollection 2018. Review.

6.

Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report.

Passweg JR, Baldomero H, Bader P, Basak GW, Bonini C, Duarte R, Dufour C, Kröger N, Kuball J, Lankester A, Montoto S, Nagler A, Snowden JA, Styczynski J, Mohty M; European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2018 Mar 14. doi: 10.1038/s41409-018-0153-1. [Epub ahead of print]

PMID:
29540849
7.

Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation.

de Koning C, Gabelich JA, Langenhorst J, Admiraal R, Kuball J, Boelens JJ, Nierkens S.

Blood Adv. 2018 Mar 13;2(5):565-574. doi: 10.1182/bloodadvances.2017015487.

8.

Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.

de Witte MA, Sarhan D, Davis Z, Felices M, Vallera DA, Hinderlie P, Curtsinger J, Cooley S, Wagner J, Kuball J, Miller JS.

Biol Blood Marrow Transplant. 2018 Mar 2. pii: S1083-8791(18)30109-5. doi: 10.1016/j.bbmt.2018.02.023. [Epub ahead of print]

PMID:
29505821
9.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

PMID:
29431743
10.

Fine-Tuning Antithymocyte Globulin Dosing and Harmonizing Clinical Trial Design.

Boelens JJ, Admiraal R, Kuball J, Nierkens S.

J Clin Oncol. 2018 Apr 10;36(11):1175-1176. doi: 10.1200/JCO.2017.77.1774. Epub 2018 Feb 7. No abstract available.

PMID:
29412785
11.

NK Cells and γδT Cells for Relapse Protection After Allogeneic Hematopoietic Cell Transplantation (HCT).

de Witte MA, Kuball J, Miller JS.

Curr Stem Cell Rep. 2017 Dec;3(4):301-311. doi: 10.1007/s40778-017-0106-4. Epub 2017 Oct 16.

PMID:
29399441
12.

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

de Bruin RCG, Veluchamy JP, Lougheed SM, Schneiders FL, Lopez-Lastra S, Lameris R, Stam AG, Sebestyen Z, Kuball J, Molthoff CFM, Hooijberg E, Roovers RC, Santo JPD, van Bergen En Henegouwen PMP, Verheul HMW, de Gruijl TD, van der Vliet HJ.

Oncoimmunology. 2017 Oct 20;7(1):e1375641. doi: 10.1080/2162402X.2017.1375641. eCollection 2017.

PMID:
29296532
13.

Jon van Rood (1926-2017).

Mueller C, Bonini C, Foeken L, Chabannon C, Bondanza A, Fleischhauer K, Velardi A, Kröger N, Kuball J, Mohty M.

Bone Marrow Transplant. 2017 Dec;52(12):1587. doi: 10.1038/bmt.2017.242. No abstract available.

PMID:
29209062
14.

CAR-T cells: the narrow path between hope and bankruptcy?

Chabannon C, Kuball J, Mcgrath E, Bader P, Dufour C, Lankester A, Basak GW, Montoto S, Nagler A, Snowden JA, Styczynski J, Duarte RF, Kröger N, Mohty M.

Bone Marrow Transplant. 2017 Dec;52(12):1588-1589. doi: 10.1038/bmt.2017.241. No abstract available.

PMID:
29209061
15.

Single Nucleotide Polymorphisms of the High Affinity IgG Receptor FcγRI Reduce Immune Complex Binding and Downstream Effector Functions.

Brandsma AM, Ten Broeke T, van Dueren den Hollander E, Caniels TG, Kardol-Hoefnagel T, Kuball J, Leusen JHW.

J Immunol. 2017 Oct 1;199(7):2432-2439. doi: 10.4049/jimmunol.1601929. Epub 2017 Aug 16.

PMID:
28814603
16.

An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia.

Shouval R, Ruggeri A, Labopin M, Mohty M, Sanz G, Michel G, Kuball J, Chevallier P, Al-Seraihy A, Milpied NJ, de Heredia CD, Arcese W, Blaise D, Rocha V, Fein J, Unger R, Baron F, Bader P, Gluckman E, Nagler A.

Clin Cancer Res. 2017 Nov 1;23(21):6478-6486. doi: 10.1158/1078-0432.CCR-17-0489. Epub 2017 Jul 28.

PMID:
28754820
17.

In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.

Oostvogels R, Uniken Venema SM, de Witte M, Raymakers R, Kuball J, Kröger N, Minnema MC.

Bone Marrow Transplant. 2017 Sep;52(9):1233-1240. doi: 10.1038/bmt.2017.141. Epub 2017 Jul 10. Review.

PMID:
28692028
18.

Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses.

Schmitt M, Schmitt A, Wiesneth M, Hückelhoven A, Wu Z, Kuball J, Wang L, Schauwecker P, Hofmann S, Götz M, Michels B, Maccari B, Wuchter P, Eckstein V, Mertens T, Schnitzler P, Döhner H, Ho AD, Bunjes DW, Dreger P, Schrezenmeier H, Greiner J.

Theranostics. 2017 Apr 10;7(6):1705-1718. doi: 10.7150/thno.18301. eCollection 2017.

19.

Correction: Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.

de Bruin RCG, Stam AGM, Vangone A, van Bergen En Henegouwen PMP, Verheul HMW, Sebestyén Z, Kuball J, Bonvin AMJJ, de Gruijl TD, van der Vliet HJ.

J Immunol. 2017 May 1;198(9):3759. doi: 10.4049/jimmunol.1700317. No abstract available.

PMID:
28416722
20.

JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement.

Snowden JA, McGrath E, Duarte RF, Saccardi R, Orchard K, Worel N, Kuball J, Chabannon C, Mohty M.

Bone Marrow Transplant. 2017 Oct;52(10):1367-1371. doi: 10.1038/bmt.2017.54. Epub 2017 Mar 27.

21.

Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis.

Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, Belitser SV, Bredius RGM, Raymakers RAP, Knibbe CAJ, Minnema MC, van Kesteren C, Kuball J, Boelens JJ.

Lancet Haematol. 2017 Apr;4(4):e183-e191. doi: 10.1016/S2352-3026(17)30029-7. Epub 2017 Mar 16.

PMID:
28330607
22.

Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report.

Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, Gennery A, Kröger N, Kuball J, Lanza F, Montoto S, Nagler A, Snowden JA, Styczynski J, Mohty M.

Bone Marrow Transplant. 2017 Jun;52(6):811-817. doi: 10.1038/bmt.2017.34. Epub 2017 Mar 13.

23.

Haematopoietic stem cell transplantation for autoimmune diseases.

Swart JF, Delemarre EM, van Wijk F, Boelens JJ, Kuball J, van Laar JM, Wulffraat NM.

Nat Rev Rheumatol. 2017 Apr;13(4):244-256. doi: 10.1038/nrrheum.2017.7. Epub 2017 Feb 23. Review.

PMID:
28228650
24.

Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation.

Steinmetz C, Kashyap A, Zhivkova N, Alizor H, Ernst I, Gottfried-Brand D, Janssen H, Teufel A, Schulze-Bergkamen H, Lotz J, Kuball J, Theobald M, Heise M, Lang H, Galle PR, Strand D, Strand S.

Hepatology. 2017 Jun;65(6):2074-2089. doi: 10.1002/hep.29072. Epub 2017 Apr 28.

PMID:
28108987
25.

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).

Blood. 2017 Mar 23;129(12):1636-1645. doi: 10.1182/blood-2016-10-740613. Epub 2017 Jan 3.

26.

Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody.

de Bruin RC, Stam AG, Vangone A, van Bergen En Henegouwen PM, Verheul HM, Sebestyén Z, Kuball J, Bonvin AM, de Gruijl TD, van der Vliet HJ.

J Immunol. 2017 Jan 1;198(1):308-317. Epub 2016 Nov 28. Erratum in: J Immunol. 2017 May 1;198(9):3759.

27.

Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.

Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, Bunjes D, Schaap N, Vigouroux S, Bacigalupo A, Veelken H, Sierra J, Eder M, Niederwieser D, Mohty M, Nagler A.

J Hematol Oncol. 2016 Nov 8;9(1):118.

28.

Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).

Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M.

Bone Marrow Transplant. 2017 Feb;52(2):191-196. doi: 10.1038/bmt.2016.258. Epub 2016 Nov 7.

PMID:
27819687
29.

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.

Carapito R, Jung N, Kwemou M, Untrau M, Michel S, Pichot A, Giacometti G, Macquin C, Ilias W, Morlon A, Kotova I, Apostolova P, Schmitt-Graeff A, Cesbron A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Lafarge X, Maumy-Bertrand M, Bertrand F, Vago L, Ciceri F, Paillard C, Querol S, Sierra J, Fleischhauer K, Nagler A, Labopin M, Inoko H, von dem Borne PA, Kuball J, Ota M, Katsuyama Y, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Milpied N, Charron D, Mohty M, Zeiser R, Socié G, Bahram S.

Blood. 2016 Oct 13;128(15):1979-1986. Epub 2016 Aug 22.

30.

Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?

van der Vlist M, Kuball J, Radstake TR, Meyaard L.

Nat Rev Rheumatol. 2016 Oct;12(10):593-604. doi: 10.1038/nrrheum.2016.131. Epub 2016 Aug 19. Review.

PMID:
27539666
31.

Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation.

Drylewicz J, Schellens IM, Gaiser R, Nanlohy NM, Quakkelaar ED, Otten H, van Dorp S, Jacobi R, Ran L, Spijkers S, Koning D, Schuurman R, Meijer E, Pietersma FL, Kuball J, van Baarle D.

J Transl Med. 2016 Aug 2;14(1):230. doi: 10.1186/s12967-016-0988-4.

32.

Cytomegalovirus Status and the Outcome of T Cell-Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

Verduyn Lunel FM, Raymakers R, van Dijk A, van der Wagen L, Minnema MC, Kuball J.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1883-1887. doi: 10.1016/j.bbmt.2016.07.009. Epub 2016 Jul 25.

33.

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Versluis J, In 't Hout FE, Devillier R, van Putten WL, Manz MG, Vekemans MC, Legdeur MC, Passweg JR, Maertens J, Kuball J, Biemond BJ, Valk PJ, van der Reijden BA, Meloni G, Schouten HC, Vellenga E, Pabst T, Willemze R, Löwenberg B, Ossenkoppele G, Baron F, Huls G, Cornelissen JJ.

Leukemia. 2017 Jan;31(1):26-33. doi: 10.1038/leu.2016.183. Epub 2016 Jun 24.

PMID:
27416910
34.

RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor.

Sebestyen Z, Scheper W, Vyborova A, Gu S, Rychnavska Z, Schiffler M, Cleven A, Chéneau C, van Noorden M, Peigné CM, Olive D, Lebbink RJ, Oostvogels R, Mutis T, Schuurhuis GJ, Adams EJ, Scotet E, Kuball J.

Cell Rep. 2016 May 31;15(9):1973-85. doi: 10.1016/j.celrep.2016.04.081. Epub 2016 May 19.

35.

Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: the Dutch experience.

van Rappard DF, Boelens JJ, van Egmond ME, Kuball J, van Hasselt PM, Oostrom KJ, Pouwels PJ, van der Knaap MS, Hollak CE, Wolf NI.

Blood. 2016 Jun 16;127(24):3098-101. doi: 10.1182/blood-2016-03-708479. Epub 2016 Apr 26. No abstract available.

36.

The next step toward GMP-grade production of engineered immune cells.

Kierkels GJ, Straetemans T, de Witte MA, Kuball J.

Oncoimmunology. 2015 Aug 27;5(2):e1076608. eCollection 2016 Feb.

37.

High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Czerw T, Labopin M, Schmid C, Cornelissen JJ, Chevallier P, Blaise D, Kuball J, Vigouroux S, Garban F, Lioure B, Fegueux N, Clement L, Sandstedt A, Maertens J, Guillerm G, Bordessoule D, Mohty M, Nagler A.

Oncotarget. 2016 May 10;7(19):27255-66. doi: 10.18632/oncotarget.8463.

38.

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.

Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, Duarte RF, Dufour C, Kuball J, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Nagler A, Sureda A, Mohty M.

Bone Marrow Transplant. 2016 Jun;51(6):786-92. doi: 10.1038/bmt.2016.20. Epub 2016 Feb 22.

39.

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T.

Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8.

40.

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.

Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, Theobald M, Graux C, Kuball J, Schouten HC, Pabst T, Löwenberg B, Ossenkoppele G, Vellenga E, Cornelissen JJ; HOVON and SAKK Leukemia Groups.

Lancet Haematol. 2015 Oct;2(10):e427-36. doi: 10.1016/S2352-3026(15)00148-9. Epub 2015 Sep 18.

PMID:
26686044
41.

Complete donor chimerism is a prerequisite for the effect of Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) on acute graft-versus-host disease.

Thus KA, de Weger RA, de Hoop TA, Boers Trilles VE, Kuball J, Spierings E.

Chimerism. 2014;5(3-4):94-8. doi: 10.1080/19381956.2015.1097025. Epub 2015 Dec 15.

42.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.

Leukemia. 2015 Oct;29(10):2062-8. doi: 10.1038/leu.2015.212. Epub 2015 Jul 31.

43.

Sufficient Immunosuppression with Thymoglobulin Is Essential for a Successful Haplo-Myeloid Bridge in Haploidentical-Cord Blood Transplantation.

Lindemans CA, Te Boome LC, Admiraal R, Jol-van der Zijde EC, Wensing AM, Versluijs AB, Bierings MB, Kuball J, Boelens JJ.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1839-45. doi: 10.1016/j.bbmt.2015.06.001. Epub 2015 Jun 26.

44.

Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.

Passweg JR, Labopin M, Cornelissen J, Volin L, Socié G, Huynh A, Tabrizi R, Wu D, Craddock C, Schaap N, Kuball J, Chevallier P, Cahn JY, Blaise D, Ghavamzadeh A, Bilger K, Ciceri F, Schmid C, Giebel S, Nagler A, Mohty M; Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT).

Bone Marrow Transplant. 2015 Aug;50(8):1063-8. doi: 10.1038/bmt.2015.121. Epub 2015 Jun 1.

PMID:
26030052
45.

Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer.

Straetemans T, Gründer C, Heijhuurs S, Hol S, Slaper-Cortenbach I, Bönig H, Sebestyen Z, Kuball J.

Clin Cancer Res. 2015 Sep 1;21(17):3957-68. doi: 10.1158/1078-0432.CCR-14-2860. Epub 2015 May 19.

46.

Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge.

de Witte MA, Kierkels GJ, Straetemans T, Britten CM, Kuball J.

Cancer Immunol Immunother. 2015 Jul;64(7):893-902. doi: 10.1007/s00262-015-1710-8. Epub 2015 May 20. Review.

47.

Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells.

Te Boome LC, Mansilla C, van der Wagen LE, Lindemans CA, Petersen EJ, Spierings E, Thus KA, Westinga K, Plantinga M, Bierings M, Broers AE, Cuijpers ML, van Imhoff GW, Janssen JJ, Huisman C, Zeerleder S, Huls G, Boelens JJ, Wulffraat NM, Slaper-Cortenbach IC, Kuball J.

Leukemia. 2015 Sep;29(9):1839-46. doi: 10.1038/leu.2015.89. Epub 2015 Apr 3.

PMID:
25836589
48.

Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Eder S, Labopin M, Arcese W, Or R, Majolino I, Bacigalupo A, de Rosa G, Volin L, Beelen D, Veelken H, Schaap NP, Kuball J, Cornelissen J, Nagler A, Mohty M; Acute Leukemia Working Party.

Eur J Haematol. 2016 Jan;96(1):90-7. doi: 10.1111/ejh.12553. Epub 2015 Apr 21.

PMID:
25807864
49.

Physiochemical disparity of mismatched HLA class I alloantigens and risk of acute GVHD following HSCT.

Kosmoliaptsis V, Jöris MM, Mallon DH, Lankester AC, von dem Borne PA, Kuball J, Bierings M, Cornelissen JJ, Groenendijk-Sijnke ME, van der Holt B, Bradley JA, Oudshoorn M, van Rood JJ, Taylor CJ, Claas FH.

Bone Marrow Transplant. 2015 Apr;50(4):540-4. doi: 10.1038/bmt.2014.305. Epub 2015 Jan 26.

PMID:
25621806
50.

Cancer Immunotherapy Using γδT Cells: Dealing with Diversity.

Scheper W, Sebestyen Z, Kuball J.

Front Immunol. 2014 Nov 20;5:601. doi: 10.3389/fimmu.2014.00601. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center